The specificity of neuroprotection by antioxidants

Table 2 Effects of Respiratory Inhibitors and Antioxidants on Oligomycin-Induced Cell Death and ROS Production

Treatments	Cell Viability (% of Control)		Percent of Oligomycin-Induced ROS Level
Treatments	Trypan	LDH	DCF	MitoSOX
Oligomycin (O), 10 μg/ml	0	0	100	100
O + Amytal, 100 μM	0	0	97 ± 3	93 ± 4
O + Rotenone, 2 μM	0	0	90 ± 5	97 ± 3
O + TTFA, 100 μM	41 ± 9*	52 ± 9*	84 ± 6*	79 ± 6*
O + Antimycin A, 2 μM	0	0	92 ± 5	114 ± 10
O + Stigmatellin, 1 μM	0	0	96 ± 5	107 ± 8
O + FCCP, 5 μM	0	0	90 ± 6	106 ± 6
O + DPI, 1 μM	0	0	97 ± 5	132 ± 8*
O + Vitamin E, 100 μM	93 ± 4*	100*	60 ± 5*	59 ± 6*
O + 2,2,5,7,8-Pentamethyl-	0	0	98 ± 5	97 ± 3
6-chromanol, 100 μM
O + Vitamin C, 100 μM	0	0	85 ± 7	91 ± 7

Cellular ROS levels were determined in HT-22 cells with CM-H₂DCFDA and MitoSOX red after 2 hr of treatment (Figure 3A) and inhibitors were added at the same time as oligomycin. Cell viability was determined after overnight treatment either by the trypan blue assay or LDH release assay. *: Significantly different from control by ANOVA (P < 0.05).

ISSN: 1423-0127